Limitations, agreements, and source contact

Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer · Source last updated 2024-01-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

limitations And Caveats

description

The study closed without meeting the total accrual goal due to contract issues with the pharma company.

point Of Contact

email

YCHAE@nm.org

organization

Northwestern University, Feinberg School of Medicine

phone

312-926-4248

title

Young Kwang Chae, MD, MPH, MBA

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice